Eikon Therapeutics, Inc. SEC filings EIKN
Eikon Therapeutics, Inc. has 67 filings in SEC EDGAR's recent list, going back to May 13, 2021. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 7, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 2, 2026 | — |
| 4 | Insider transaction | Sep 8, 2026 | Sep 3, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 6, 2026 | — |
| 3 | Initial insider ownership | Jun 15, 2026 | Jun 15, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 13, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 6, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 29, 2026 | — |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 18, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 12, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 11, 2026 | — |
| 4 | Insider transaction | Feb 10, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 9, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EIKN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Millbrae, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1861123
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.